-transparent.png){kind=logo}
A nationwide study was conducted to investigate the efficacy of Clarithromycin (CAM) on pulmonary atypical mycobacteriosis caused by the Mycobacterium avium-Mycobacterium intracellulare complex, including intractable cases. Out of total 97 patients examined, the analysis for bacteriological efficacy was possible in 69 cases. The negative conversion of bacilli was observed in 18 cases (26.1%), and 5 out of 12 cases in which the follow-up was conducted turned out continued negative status. The efficacy of CAM was relatively high in the following cases: the duration of the disease was less than 6 months the extent of pulmonary lesions on chest roentogenograms was limited or moderate; and antituberculous agents which were previously unused were applied in combination with CAM. Also, the efficacy was high in cases where the dose of CAM was 600 mg/day or higher. Major side effect was mill to moderate digestive symptoms. In conclusion, at daily dose of 600 mg or higher, CAM was effective in the elimination or reduction of M avium M. intracellulare complex that caused atypical mycobacteriosis, without developing serious side effect. Treatment with this drug should be attempted in intractable cases.
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
January 2005,
Kekkaku : [Tuberculosis],
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
June 1996,
American journal of respiratory and critical care medicine,
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
May 1994,
American journal of respiratory and critical care medicine,
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
April 2010,
The American journal of medicine,
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
January 2000,
Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
January 1997,
Drugs,
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
September 2002,
Clinics in chest medicine,
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
April 1987,
The Japanese journal of antibiotics,
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
May 2010,
Kekkaku : [Tuberculosis],
M Yamamoto, and
F Kuze, and
M Sakatani, and
H Saito, and
H Shimoide, and
R Soejima, and
K Hara
January 2006,
Internal medicine (Tokyo, Japan),
